The Empire State Building Celebrates Romance in NYC with Valentine’s Day Experiences Throughout the Month of February
7.2.2023 18:56:00 EET | Business Wire | Press release
Love is in the air at the Empire State Building (ESB) with a Valentine’s Day celebration that includes an unforgettable proposal package, tower lighting, giveaways, and month-long special offers for visitors this February.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207005876/en/
Empire State Building Valentine's Day 86th Floor Observatory (Photo: Business Wire)
- Happily Ever Empire – Each couple that books the popular Happily Ever Empire engagement package – that includes priority access and a private tour of the Observatory with celebratory champagne – for Feb. 10-14 will be gifted a four-night, five-day luxury all-inclusive getaway by Sandals Resorts to the resort of their choice (terms and conditions apply) – that includes the brand new Sandals Dunn’s River that opens in Ocho Rios, Jamaica in May – and a $250 gift card towards a wedding dress courtesy of Kleinfeld Bridal. Happily Ever Empire engagement packages are limited to five bookings per day.
- Getaway Giveaway – Visitors to the Observatory Experience from Feb. 10-14 can enter to win a four-night, five-day all-inclusive resort stay courtesy of Sandals Resorts when they post a photo from the special Valentine’s Day photo corner on the 86th Floor Observatory and tag @sandalsresorts on Instagram.
- Spread the Love – All visitors who purchase tickets on the ESB website during the month of February will receive 10 percent off online orders from Magnolia Bakery, 25 percent off Valentine’s Day flowers from FTD Flowers, and 20 percent off online orders from Tony’s Chocolonely from Feb. 6-14. On Feb. 11 from 2-8 pm, Tony’s Chocolonely will show love with free chocolate heart samples on the 86th Floor Observatory.
- Love Lights – On Feb. 14, the Empire State Building’s world-famous tower lights will shine in a pink heartbeat as a Valentine’s Day gift to New York City.
“The reimagined Observatory at the World’s Most Romantic Building draws visitors from around the world for an authentic experience in the heart of New York City,” said Jean-Yves Ghazi, president of the Empire State Building Observatory. “Our remarkable views provide visitors with the perfect backdrop for an over-the-top date or proposal.”
“It’s the season of romance and as a brand founded on all things love, Sandals Resorts is here to remind couples of the importance of celebrating love,” said Luisana Suegart, director of public relations for the worldwide representatives of Sandals Resorts. “Recent studies from our Institute of Romance found that a key ingredient in thriving relationships is making the time for connection, with couples feeling closest to each other while on vacation and, forget the chocolates, most agreeing that a getaway is the most romantic gift. Gifting these special couples an idyllic Caribbean escape is our way of celebrating such an important milestone.”
Hi-res imagery and b-roll of the Empire State Building, the scheduled Valentine’s Day tower lighting and all the upcoming exclusive offerings can be downloaded here .
More information about the Empire State Building Observatory can be found online.
About the Empire State Building
The Empire State Building, the “World's Most Famous Building," owned by Empire State Realty Trust, Inc. (ESRT: NYSE), soars 1,454 feet above Midtown Manhattan from base to antenna. The $165 million reimagination of the Empire State Building Observatory Experience creates an all-new experience with a dedicated guest entrance, an interactive museum with nine galleries, and a redesigned 102nd Floor Observatory with floor-to-ceiling windows. The journey to the world-famous 86th Floor Observatory, the only 360-degree, open-air observatory with views of New York and beyond, orients visitors for their entire New York City experience and covers everything from the building's iconic history to its current place in pop culture. Learn more at www.esbnyc.com. Declared "America's Favorite Building" by the American Institute of Architects, the world's most popular travel destination by Uber, the #1 Attraction in the United States in Tripadvisor’s 2022 Travelers’ Choice Best of the Best, and the #1 New York City attraction by Lonely Planet, it welcomes more than 4 million annual visitors from around the world.
Since 2011, the building has been fully powered by renewable wind electricity, and its many floors primarily house a diverse array of office tenants such as LinkedIn and Shutterstock, as well as retail options like STATE Grill and Bar, Tacombi, and Starbucks. For more information and Observatory Experience tickets visit esbnyc.com or follow the building's Facebook, Twitter, Instagram, Weibo, YouTube, or TikTok.
Source: Empire State Realty Trust, Inc.
Category: Observatory
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005876/en/
Contact information
MEDIA:
Empire State Realty Trust
Brock Talbot
347-804-7863
btalbot@esrtreit.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom